Mulkearns Hubert E, Torre Healy L, Silver D, Eurich J, Bayık D, Serbinowski E, et al. Development of a Cx46 Targeting Strategy for Cancer Stem Cells. Cell Rep. 2019;27:1062-1072.e5 pubmed publisher

Ajmal M, Almutairi F, Zaidi N, Alam P, Siddiqi M, Khan M, et al. Biophysical insights into the interaction of clofazimine with human alpha 1-acid glycoprotein: a multitechnique approach. J Biomol Struct Dyn. 2019;37:1390-1401 pubmed publisher

Murashov M, Lalone V, Rzeczycki P, Keswani R, Yoon G, Sud S, et al. The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation. J Invest Dermatol. 2018;138:697-703 pubmed publisher

Officioso A, Alzoubi K, Manna C, Lang F. Clofazimine Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem. 2015;37:331-41 pubmed publisher

Faouzi M, Starkus J, Penner R. State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine. Br J Pharmacol. 2015;172:5161-73 pubmed publisher

Kaiser M, Maser P, Tadoori L, Ioset J, Brun R. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning. PLoS ONE. 2015;10:e0135556 pubmed publisher

Panić G, Vargas M, Scandale I, Keiser J. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9:e0003962 pubmed publisher

Shimokawa Y, Yoda N, Kondo S, Yamamura Y, Takiguchi Y, Umehara K. Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes. Biol Pharm Bull. 2015;38:1425-9 pubmed publisher

Vocat A, Hartkoorn R, Lechartier B, Zhang M, Dhar N, Cole S, et al. Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:4012-9 pubmed publisher

Koot D, Cromarty D. Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation. Drug Deliv Transl Res. 2015;5:257-67 pubmed publisher

Tyagi S, Ammerman N, Li S, Adamson J, Converse P, Swanson R, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A. 2015;112:869-74 pubmed publisher

Grossman T, Shoen C, Jones S, Jones P, Cynamon M, Locher C. The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob Agents Chemother. 2015;59:1534-41 pubmed publisher

Marcos L, Conerly S, Walker S. Leprosy. Am J Trop Med Hyg. 2014;91:216 pubmed publisher

Srikanth C, Joshi P, Bikkasani A, Porwal K, Gayen J. Bone distribution study of anti leprotic drug clofazimine in rat bone marrow cells by a sensitive reverse phase liquid chromatography method. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;960:82-6 pubmed publisher

Adams K, Szumowski J, Ramakrishnan L. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis. 2014;210:456-66 pubmed publisher

Oh C, Moon C, Park O, Kwon S, Jang J. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J Antimicrob Chemother. 2014;69:1599-607 pubmed publisher

Yoo J, Lyu J, Lee S, Kim W, Kim D, Shim T. Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence]. Int J Tuberc Lung Dis. 2013;17:1243-4 pubmed publisher

Grosset J, Tyagi S, Almeida D, Converse P, Li S, Ammerman N, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med. 2013;188:608-12 pubmed publisher

Hossain D. Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients. Lepr Rev. 2013;84:105-12 pubmed

Gopal M, Padayatchi N, Metcalfe J, O Donnell M. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013;17:1001-7 pubmed publisher

Bhaumik S. Clofazimine should be used in all cases of leprosy, says Indian research council. BMJ. 2013;346:f1963 pubmed publisher

Paniz Mondolfi A, Cressey B, Ahmad A, Tapia Centola B, Cohen L, Mahmoodi M. Granulomatous alopecia: a variant of alopecia areata?. J Cutan Pathol. 2013;40:357-60 pubmed publisher

Tirhazouine I, Chiheb S, Hali F, Rifki A, Benchikhi H. [Histoid leprosy]. Ann Dermatol Venereol. 2013;140:244-5 pubmed publisher

Weberschock T, Göttig S. A young man with livid facial nodules and a loss of eyebrows. Lancet Infect Dis. 2013;13:276 pubmed publisher

Massone C, Clapasson A, Nunzi E. Borderline lepromatous leprosy in an Italian man. Am J Trop Med Hyg. 2013;88:211 pubmed publisher

Deps P, Guerra P, Nasser S, Simon M. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. Lepr Rev. 2012;83:305-7 pubmed

Cunha M, Virmond M, Schettini A, Cruz R, Ura S, Ghuidella C, et al. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil. Lepr Rev. 2012;83:261-8 pubmed

Lockwood D, Cunha M. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally. Lepr Rev. 2012;83:241-4 pubmed

Wu X, Cherian P, Lee R, Hurdle J. The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother. 2013;68:806-15 pubmed publisher

Baik J, Stringer K, Mane G, Rosania G. Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response. Antimicrob Agents Chemother. 2013;57:1218-30 pubmed publisher

Degang Y, Akama T, Hara T, Tanigawa K, Ishido Y, Gidoh M, et al. Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages. PLoS Negl Trop Dis. 2012;6:e1936 pubmed publisher

Rodríguez G, Abaúnza M, Vargas E, Lopez F. [Leprosy and the testis]. Biomedica. 2012;32:13-22 pubmed publisher

Verma R, Germishuizen W, Motheo M, Agrawal A, Singh A, Mohan M, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother. 2013;57:1050-2 pubmed publisher

Bailly N, Thomas M, Klumperman B. Poly(N-vinylpyrrolidone)-block-poly(vinyl acetate) as a drug delivery vehicle for hydrophobic drugs. Biomacromolecules. 2012;13:4109-17 pubmed publisher

Baik J, Rosania G. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS ONE. 2012;7:e47494 pubmed publisher

Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2013;68:284-93 pubmed publisher

van Ingen J, Totten S, Helstrom N, Heifets L, Boeree M, Daley C. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56:6324-7 pubmed publisher

Wang T, Lee M, Choi E, Pardo Villamizar C, Lee S, Yang I, et al. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel. PLoS ONE. 2012;7:e43950 pubmed publisher

Zhang D, Lu Y, Liu K, Liu B, Wang J, Zhang G, et al. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J Med Chem. 2012;55:8409-17 pubmed publisher

Zhang M, Sala C, Hartkoorn R, Dhar N, Mendoza Losana A, Cole S. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother. 2012;56:5782-9 pubmed publisher

Adar T, Tayer Shifman O, Mizrahi M, Tavdi S, Barak O, Shalit M. Dapsone induced eosinophilic pneumonia. Eur Ann Allergy Clin Immunol. 2012;44:144-6 pubmed

Grant S, Kaufmann B, Chand N, Haseley N, Hung D. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci U S A. 2012;109:12147-52 pubmed publisher

Madke B, Ghia D, Gadkari R, Nayak C. Cheilitis granulomatosa (Miescher granulomatous macrocheilitis) with trisomy 21. Dermatol Online J. 2012;18:7 pubmed

Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, et al. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis. 2012;16:1119-25 pubmed publisher

Cholo M, Steel H, Fourie P, Germishuizen W, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012;67:290-8 pubmed publisher

Gurfinkel P, Pina J, Ramos e Silva M. Use of clofazimine in dermatology. J Drugs Dermatol. 2009;8:846-51 pubmed

. Clofazimine. Tuberculosis (Edinb). 2008;88:96-9 pubmed publisher

Pais A, Pereira S, Garg I, Stephen J, Antony M, Inchara Y. Intra-abdominal, crystal-storing histiocytosis due to clofazimine in a patient with lepromatous leprosy and concurrent carcinoma of the colon. Lepr Rev. 2004;75:171-6 pubmed

Ridder G, Fradis M, Lohle E. Cheilitis granulomatosa Miescher: treatment with clofazimine and review of the literature. Ann Otol Rhinol Laryngol. 2001;110:964-7 pubmed

Sanchez M. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine. Clin Dermatol. 2000;18:131-45 pubmed

O CONNOR R, O Sullivan J, O Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab Rev. 1995;27:591-614 pubmed

Arbiser J, Moschella S. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995;32:241-7 pubmed

Holdiness M. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet. 1989;16:74-85 pubmed

Garrelts J. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP. 1991;25:525-31 pubmed

Kumar B. Clofazimine--a review. Indian J Lepr. 1991;63:78-92 pubmed

Freerksen E, Seydel J. Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Arzneimittelforschung. 1992;42:1243-5 pubmed